Last reviewed · How we verify
Fairhaven Pro for men
Fairhaven Pro for men is a Small molecule drug developed by Hamad Medical Corporation. It is currently FDA-approved. Also known as: Antioxidant.
Fairhaven Pro for men is a small molecule that acts as an opener of the sulfonylurea receptor 2, Kir6.2. It is being studied in clinical trials for its potential effects on oxidative stress in semen and male infertility.
At a glance
| Generic name | Fairhaven Pro for men |
|---|---|
| Also known as | Antioxidant |
| Sponsor | Hamad Medical Corporation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fairhaven Pro for men CI brief — competitive landscape report
- Fairhaven Pro for men updates RSS · CI watch RSS
- Hamad Medical Corporation portfolio CI
Frequently asked questions about Fairhaven Pro for men
What is Fairhaven Pro for men?
Who makes Fairhaven Pro for men?
Is Fairhaven Pro for men also known as anything else?
What development phase is Fairhaven Pro for men in?
Related
- Manufacturer: Hamad Medical Corporation — full pipeline
- Also known as: Antioxidant
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing